Archimedes Pharma Limited

Archimedes Pharma Announces Ground Breaking Phase III Data Showing NasalFent to be Superior to the Standard of Care for Breakthrough Cancer Pain

Archimedes Pharma Announces Ground-Breaking Phase III Data Showing NasalFent to be Superior to the Standard of Care for Breakthrough Cancer Pain

READING, England - Meets Primary Efficacy Endpoint - First Study of a Next Generation Fentanyl Based Product to Show Superiority Over Immediate Release Morphine Archimedes Pharma Limited, the UK based, pan-European specialty pharmaceutical company, today announces new positive headline phase III results for NasalFent(R), the Company's innovative and highly differentiated fentanyl citrate nasal spray, developed for the rapid relief of breakthrough cancer pain.

MORE..

Older News

READING, England - Meets Primary Efficacy Endpoint - First Study of a Next-Generation Fentanyl-Based Product to Show Superiority Over Immediate Release Morphine Archimedes Pharma Limited, the UK-based, pan-European specialty pharmaceutical company, today announces new positive headline phase III results for NasalFent(R), the Company's innovative and highly differentiated fentanyl citrate nasal spray, developed for the rapid relief of breakthrough cancer pain.

MORE..